Curis, Inc.
(NASDAQ : CRIS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.76%195.471.3%$555.99m
GILDGilead Sciences, Inc.
0.24%66.520.9%$368.70m
ALXNAlexion Pharmaceuticals, Inc.
-0.79%107.402.0%$321.44m
ILMNIllumina, Inc.
1.14%300.913.5%$301.00m
BIIBBiogen Inc.
1.86%236.631.3%$288.49m
CELGCelgene Corporation
-0.23%98.401.3%$282.90m
AAgilent Technologies, Inc.
0.43%77.901.6%$193.04m
SRPTSarepta Therapeutics, Inc.
-2.25%86.0014.7%$180.31m
VRTXVertex Pharmaceuticals Incorporated
1.44%174.941.9%$173.66m
REGNRegeneron Pharmaceuticals, Inc.
-0.90%281.622.6%$171.53m
EXASExact Sciences Corporation
-1.82%106.7124.1%$132.03m
ACADACADIA Pharmaceuticals Inc.
3.35%40.4513.9%$98.63m
INCYIncyte Corporation
0.47%76.432.5%$83.43m
BMRNBioMarin Pharmaceutical Inc.
-0.21%72.654.3%$76.16m
IONSIonis Pharmaceuticals, Inc.
-1.02%66.208.2%$63.42m

Company Profile

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.